Allurion Technologies Q4 2025 Results: Stock Slumps Amid Weak Valuation
Allurion Technologies Q4 2025 earnings reveal investor skepticism amid promising balloon‑based obesity solutions, showing volatile stock and low valuation.
2 minutes to read
Allurion Technologies Inc
Allurion Q3 2025 Update: Revenue Drop, FDA Milestones, and $5M Funding Boost
Allurion Technologies reports Q3 earnings, sharp revenue drop, but new FDA milestones and a debt‑free strategy hint at a potential rebound.
2 minutes to read